% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mr_ssssamsa mr_ssssamsa Oct 14, 2010 12:07 PM Flag


    One more comment about SN-2310. It didn't produce the early-onset diarrhea that's one of the worst side effects of Irinotecan. So if it works, it would probably displace Irinotecan, which as I mentioned has around $1 billion in annual sales, pretty quickly. In preclinical tests it was much more effective than Irinotecan. So even though it didn't show much efficacy in the phase 1 trial, I suspect someone will be interested in licensing it.

3.25+0.09(+2.85%)11:56 AMEDT